Opinion|Videos|December 9, 2024
Disability Accumulation and Early Therapy: Insights from MAGNIFY-MS and High-Efficacy DMT Data
Author(s)Gabriel Pardo, MD, FAAN, Martin Belkin, DO
Key Takeaways
- Cladribine reduces disability accumulation in both treatment-naive and previously treated patients, highlighting the importance of early therapy initiation.
- High-efficacy DMTs, including ocrelizumab, ofatumumab, and S1P receptor modulators, effectively manage PIRA and mitigate disability progression.
Panelists discuss how the MAGNIFY-MS study underscores the significance of early, aggressive multiple sclerosis (MS) treatment with cladribine, demonstrating its potential to effectively mitigate disability progression through progression independent of relapse activity (PIRA) suppression in both treatment-naive and previously treated patient populations, with outcomes competitive with other high-efficacy disease-modifying therapies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Stefano et al presented data on disability accumulation (PIRA, relapse-associated worsening, confirmed disability accumulation) with cladribine from the MAGNIFY-MS study that show the importance of early initiation of therapy. Please highlight disability accumulation in both treatment-naive and previously treated groups.
- Please share an overview of PIRA data with other high-efficacy disease-modifying therapies (DMTs) (ocrelizumab, ofatumumab, S1P receptor modulators, etc).
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Discontinuing Disease-Modifying Therapy in Older Patients With MS: John Corboy, MD
2
Stem Cell Therapy Versus Traditional Parkinson Treatments
3
What Clinicians Need to Know About Emerging Stem Cell Therapies for Parkinson Disease
4
Mapping the Clinical Trial Landscape for Stem Cell Therapies in Parkinson Disease
5